Technical Committee Chair (In no particular order)
Yicheng Ni
LaboHeal Chief Oncology Expert; Professor, Zhongda Hospital Affiliated to Southeast University, China.
Research field: Image-guided Diagnosis and Treatment Integration, AI Medical Imaging, Tumor and Cancer Treatment, Medical Robots, Targeted Therapy, Medical Imaging, and Cancer Modeling.
Professor Yicheng Ni is a Changjiang Scholar Professor and Professor of Radiology at Zhongda Hospital Affiliated to Southeast University. He received his undergraduate and master's degrees from Nanjing Medical University and his doctorate from KU Leuven (a top 50 university globally) in Belgium in 1995. He was then exceptionally retained by KU Leuven and appointed as a tenured professor, founding and serving for many years as the director of the "Therapeutic Integration Laboratory" at KU Leuven until his honorable retirement in 2022. In 2023, Professor Ni was selected for the Ministry of Education's Changjiang Scholar Professor Program and became a full-time faculty member at Zhongda Hospital Affiliated to Southeast University. Professor Ni has long been dedicated to research in the field of medical imaging, conducting original research and clinical translation on major diseases threatening human health (such as cancer and cardiovascular diseases) based on image-guided navigation technology. He has led EU research projects and National Natural Science Foundation of China projects, published hundreds of SCI papers and monographs, holds more than ten international patents, and has received dozens of domestic and international awards. He is the only person in the world to have received both the Herbert M. Stauffer Award in medical imaging and the Elliott Lasser Award in contrast agents. He has been selected as one of the top 2% of scientists globally and ranked first in his special category by an internationally authoritative KOL (Key Opinion Leaders) organization. To date, Professor Ni has mentored dozens of postdoctoral fellows, doctoral students, and master's students, many of whom have become chief scientists, discipline leaders, or key personnel at renowned institutions both domestically and internationally, including Harvard University, Stanford University, Cambridge University, Zhejiang University, and Nanjing Medical University.
Liwu Fu
Sun Yat-sen University Cancer Center, China.
Research field: Anticancer Drug Pharmacology, Toxicology, Molecular Mechanism Of Anticancer Drugs And Individual Cancer Chemotherapy.
Dr. Liwu Fu, Professor, Director, Department of Experimental Research (Cancer Institute), Cancer Center, Sun Yat-sen University, Guangzhou, China. He received his Ph. D. degree from Sun Yat-sen University in 1996. And then he became an assistant professor, associated professor and full professor in Cancer Center, Sun Yat-sen University. He also stayed in Medical University of South Carolina as postdoctoral fellowship from 1999 to 2001. His active research fields include (1) reversal multidrug resistance induced by ABC transporters, (2) new drug research and development for treatment of cancer patients, (3) primary cancer tissue culture and test of drug sensitivity for personalized chemotherapy. He got a lot of research foundations from 863 projects (PI and Co-PI), 973 project (Co-PI), National Natural Scientific Foundations of China, and so on. He published more than 250 papers including Nature Communication, Cancer Res, Inter J Cancer, Cell Cycle, Mol Med, Mol Cancer Ther, Mol Pharm, Mol Pharmacol, Br J Pharmacol, Biochem Pharmacol etc. journals. He applied for 12 patents. He is Chairman of Board of Directors, Guangdong Anticancer Society; Associate Director, Cancer Pharmacology and Chemotherapy Section, Chinese Pharmacological Society; Associate Director, Anticancer Drug Section, Chinese Anticancer Society; Active Member of AACR; Member of Board of Directors, Guangdong Pharmacological Society; Member of Chinese Pharmacological Society.
Peixin Dong
Researcher, Hokkaido University, Japan.
Research field: Epigenetic And Genetic Mechanisms That Underpin Cancer Stem Cells, Emt, Chemoresistance, And Cancer Metastasis.
Dr. Dong Peixin currently is the Researcher of Hokkaido University, Japan. He is interested in the epigenetic and genetic mechanisms that underpin cancer stem cells, EMT, chemoresistance, and cancer metastasis. Dr. Dong has developed expertise via more than 70 papers in international journals. Dr. Dong is an Associate Editor for the journals Frontiers in Pharmacology, Frontiers in Oncology, BMC Cancer, Journal of Cellular and Molecular Medicine, and Current Gene Therapy. Dr. Dong is also a member of the Editorial Boards of Clinical & Experimental Metastasis, PLOS ONE, Genes, Biomolecules, Bioengineered, Chinese Clinical Oncology, and Gynecology and Pelvic Medicine. Dr. Dong has earned several awards for his contributions to the field.
Technical Committee Member (In no particular order)
Ahmed N. Abdalla, Huaiyin Institute of Technology, China
Alicia Cristina Peña Romero, National Cancer Center Hospital East, Tokyo University of Science, Japan
Alireza Heidari, California South University, USA
Ata Jahangir Moshayedi, Jiangxi University of Science and Technology, China
Carmen Martos, Fundació Fisabio, Spain
Christopher L. Antos, ShanghaiTech University, China
Congcong Zhou, Zhejiang University, China
Dipayan Rudra, ShanghaiTech University, China
Farid Menaa, CIC-Fluorotronics, Inc., USA
Hua Su, Fudan Univeristy, China
James L Cox, A.T. Still University, USA
Jones Gyamfi, Teesside University, UK
Jun Zhang, University of Kansas Medical Center, USA
Lanzhen Zhang, Beijing University of Chinese Medicine, China
Luca Roncati, Link Campus University, Italy
Ludovica Gaiaschi, University of Pavia, Italy
Michel Mickael, Polish Academy of Science, Poland
Milad Adel, Agricultural Research Education and Extension Organization (AREEO), Iran
Ming Chen, Zhejiang University, China
Ming-Ling Chang, Chang Gung Memorial Hospital, China
Mohammad Ali Moni, The University of Queensland, Australia
Mohanad S AL-Musaylh, Southern Technical University, Iraq
Mokhnache Mohamed, Ferhat ABBAS University, Algeria
Morteza Hosseini, University of Tehran, Iran
Mostafa Gouda, Zhejiang University, China
Muhammad Asif Ali, University of Veterinary and Animal Sciences, Pakistan
Olamide Animasahun, University of Michigan, USA
Orestis Ioannidis, Aristotle University of Thessaloniki, Greece
Peng Yuan, Cancer Hospital Chinese Academy of Medical Sciences, China
Rohit Gundamaraju, Icahn School of Medicine at Mount Sinai, USA
Sansanee Auephanwiriyakul, Chiang Mai University, Thailand
Sasidharan Sreenivasan, Universiti Sains Malaysia, Malaysia
Shun-Qing (Simon) Liang, University of Minnesota Twin Cities, USA
Sreyashi Das, University of Florida, USA
Sreyashi Das, Louisiana State University, USA
Sumaira Anjum, Kinnaird College For Women University, Pakistan
Surajit Pathak, Chettinad Academy of Research & Education (CARE), India
Tan Xiao Jian, Tunku Abdul Rahman University of Management and Technology, Malaysia
Tao Liu, University of New South Wales, Australia
Vinayak Adimule, Angadi Institute of Technology and Management, India
William C. Cho, Queen Elizabeth Hospital, China
Zeliha Selamoglu, Nigde Omer Halisdemir University, Turkey
Zhenhua Li, China Medical University, China
Zhichao Dong, The First Affiliated Hospital of Dalian Medical University, China
Zhiling Yu, Hong Kong Baptist University, China
Zulqarnain Baloch, Kunming University of Science and Technology, China